Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Legend Capital Invests in Nuwacell Biotechnologies

main

09_13 Legend Capital Invests in Nuwacell

Legend Capital Invests in Nuwacell Biotechnologies 

Legend Capital Invests in Nuwacell Biotechnologies

Related Content

Antitrust and Competition Life Sciences Year in Review 2024

Antitrust and Competition Life Sciences Year in Review 2024

First Circuit Adopts Defense-Friendly “But-For” Causation Standard for AKS-Predicated FCA Claims

FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes

IP Litigator Publishes Goodwin Partners’ BPCIA Research

UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine

Regulatory Updates on Samsung’s Denosumab Biosimilars

Dr. Reddy’s Secures License from Henlius to Market Daratumumab Biosimilar in the U.S. and Europe

Goodwin’s Annual Healthcare & Life Sciences Summit

Yale OCS STEM PhD Pathways: Navigating Career Paths in Patent Law with Miho Kaneko

Bpifrance and Andera Partners Invest in the €27 Million Series B Financing of EG 427

Goodwin Advises Atrandi Biosciences in $25M Series A Financing

Stilla Technologies and the Sellers Sign a Put Option Agreement for the Acquisition of Stilla Technologies by Bio-Rad

Chambers Global 2025 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders

Goodwin Advises Sionna Therapeutics on the Closing of its $219.2 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Anthos Therapeutics To Be Acquired by Novartis For Up To $3.1 Billion

Life Sciences

Private Equity

Life Sciences Asia

Venture Capital